Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;26(5):550-7.
doi: 10.3978/j.issn.1000-9604.2014.10.02.

Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer

Xu Liang  1 , Lijun Di  1 , Guohong Song  1 , Ying Yan  1 , Chaoying Wang  1 , Hanfang Jiang  1 , Huiping Li  1
Affiliations

Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer

Xu Liang et al. Chin J Cancer Res. 2014 Oct.

Abstract

Objective: To investigate the efficacy and safety of capecitabine maintenance therapy (MT) after initial capecitabine plus docetaxel (XT) chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC).

Methods: Fifty-five mTNBC patients treated with XT chemotherapy between May 2007 and June 2013 were retrospectively analyzed. When initial disease control was achieved by the combination chemotherapy, capecitabine was continued for 32 patients (MT), while 23 patients remained without any treatment (non-MT). We compared progression-free survival (PFS) and safety of both groups.

Results: The median PFS of 55 patients was 8.1 months, overall median PFS time of 32 patients in the capecitabine MT group and 23 in the non-MT group was 10.1 vs. 6.7 months (P=0.032), respectively. When compared PFS time of maintenance treatment, single-agent capecitabine prolonged PFS by 7.1 months, for non-MT patients, the PFS without any treatment was 3.1 months, and this between-group difference was statistically significant (P=0.003). Adverse events, including of hematologic toxicity, gastrointestinal toxicities, hand-foot syndrome and abnormal liver function were not significantly different between two groups.

Conclusions: After initial disease control was achieved with the XT combination chemotherapy, capecitabine MT can significantly prolong PFS time with a favorable safety profile in mTNBC patients.

Keywords: Capecitabine; maintenance therapy (MT); metastatic breast cancer (MBC); triple-negative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median progression-free survival (PFS) of 55 mTNBC patients with capecitabine plus docetaxel (XT) combined chemotherapy. mTNBC, etastatic triple-negative breast cancer.
Figure 2
Figure 2
Median progression-free survival (PFS) of MT group and non-MT group. MT, maintenance therapy.
Figure 3
Figure 3
Median progression-free survival (PFS) of capecitabine single-agent maintenance in MT group and non-treatment in non-MT group. MT, maintenance therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15Suppl 5:39-48. - PubMed
    1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52. - PubMed
    1. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8. - PMC - PubMed
    1. Bidard FC, Conforti R, Boulet T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol 2007;18:1285-6. - PubMed
    1. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74. - PubMed